5 Breakthrough Multiple Sclerosis Treatments in 2025

Multiple sclerosis (MS) care is evolving fast, with new options that aim not just to control relapses but to protect—and even repair—the nervous system. For people and families navigating MS, understanding what’s new, what’s promising, and what’s already available can make a meaningful difference in day‑to‑day life and long‑term outcomes.

What makes these advances different?

For years, most Multiple Sclerosis treatments focused on reducing inflammation and relapse rates. That strategy works for many, but it doesn’t fully address the slow nerve damage that drives disability—especially in progressive forms of MS. The most exciting wave of research now targets both arms: dialing down harmful immune activity while promoting neuroprotection and, in some cases, remyelination (repairing the protective coating around nerve fibers).

Equally important, new therapies are being designed to penetrate the central nervous system, act on key immune pathways inside the brain and spinal cord, and reduce treatment burden with less frequent dosing or shorter infusions. This matters for quality of life and long‑term adherence—two factors that strongly influence outcomes.

Finally, clinical trials are increasingly using sensitive biomarkers—such as neurofilament light chain (NfL)—to detect nerve injury early and personalize treatment decisions. This shift supports more precise, proactive care rather than a one‑size‑fits‑all approach. You can track ongoing trials at ClinicalTrials.gov and patient‑friendly updates from the National Multiple Sclerosis Society.

5 Breakthrough Multiple Sclerosis Treatments

1) Brain‑penetrant BTK inhibitors (next‑gen oral immunomodulators)

What they are: Bruton’s tyrosine kinase (BTK) inhibitors are oral drugs that modulate B‑cells and myeloid cells—key players in MS inflammation—inside and outside the brain. Unlike traditional therapies that mainly act in the bloodstream, BTK inhibitors are designed to cross the blood–brain barrier and may help address smoldering disease activity.

Why it’s a breakthrough: By targeting immune cells within the central nervous system, BTK inhibitors could help with both relapse control and neurodegeneration. Multiple late‑stage trials are underway or recently reported for agents such as fenebrutinib, tolebrutinib, and others. Early data suggest meaningful reductions in relapse rates and MRI activity versus standard comparators in relapsing MS, with ongoing studies in progressive MS.

Where to learn more: See overviews from the National MS Society and check current studies at ClinicalTrials.gov. As with any new class, long‑term safety (for example, liver and infection risks) is being closely monitored—discuss the risk–benefit profile with your neurologist.

2) Ublituximab (Briumvi): faster anti‑CD20 infusions

What it is: Ublituximab is an anti‑CD20 monoclonal antibody that depletes B‑cells—an approach proven highly effective in relapsing forms of MS. It’s FDA‑approved for relapsing MS and is known for shorter infusion times compared with earlier anti‑CD20 options, which can reduce time in the clinic.

Why it’s a breakthrough: In large head‑to‑head trials against an established oral therapy (teriflunomide), ublituximab significantly reduced annualized relapse rates and MRI lesion activity. For many patients who need high‑efficacy therapy, the combination of robust B‑cell depletion and streamlined infusion logistics is a compelling option.

Where to learn more: Review treatment basics at Mayo Clinic, patient resources via the National MS Society, and regulatory/clinical details through ClinicalTrials.gov or the manufacturer’s site (Briumvi.com).

3) Autologous hematopoietic stem cell transplantation (AHSCT/HSCT)

What it is: AHSCT is a one‑time, hospital‑based procedure that “resets” the immune system. Doctors collect a patient’s stem cells, use chemotherapy to ablate immune cells driving MS, and then reinfuse the stem cells to rebuild a healthier immune repertoire.

Why it’s a breakthrough: In randomized studies of highly active relapsing MS, AHSCT has shown dramatic reductions in relapses and new MRI lesions, with many participants experiencing prolonged periods free of disease activity. For carefully selected patients—often those who continue to relapse despite high‑efficacy drugs—AHSCT can offer durable control with a single intensive intervention.

Important caveats: AHSCT isn’t for everyone. It carries short‑term risks (infections, low blood counts) and requires experienced centers. Talk with an MS specialist about eligibility, center expertise, and insurance coverage. The National MS Society provides guidance and links to transplant programs; trial information is available at ClinicalTrials.gov.

4) Remyelination strategies (from repurposed drugs to cell therapies)

What they are: Remyelination aims to restore the myelin sheath around damaged nerves to improve conduction and protect axons. Approaches include repurposed small molecules (such as clemastine) and experimental biologics or cell therapies that recruit or replace oligodendrocyte progenitor cells.

Why it’s a breakthrough: Early randomized studies of clemastine showed modest improvements in visual pathway conduction in MS‑related optic nerve damage—proof that remyelination in people is possible. While several high‑profile agents have not met endpoints, the field has learned how to design better trials and select patients more likely to respond, accelerating next‑generation candidates.

Where to learn more: Follow research roundups from the Multiple Sclerosis International Federation (MSIF) and the National MS Society. Ask your neurologist whether any remyelination trials are recruiting near you and whether your disease profile makes you a good candidate.

5) Targeting Epstein–Barr virus (EBV) in MS

What it is: A growing body of evidence links prior EBV infection to MS risk. New strategies include preventive or therapeutic EBV vaccines and adoptive T‑cell therapies that bolster the immune system’s control of EBV‑infected cells.

Why it’s a breakthrough: If EBV proves to be a key upstream driver, EBV‑targeted approaches could change the game—reducing relapses, lowering the chance of progression, or eventually preventing MS altogether. Several early‑ and mid‑stage trials are underway to test safety and signals of efficacy.

Where to learn more: You can monitor EBV‑focused studies on ClinicalTrials.gov and read accessible summaries from national patient organizations. Because this area is rapidly evolving, revisit sources every few months for updates.

How these differ from traditional therapies

Conventional disease‑modifying therapies (DMTs)—including interferons, glatiramer acetate, S1P modulators, fumarates, and first‑generation monoclonal antibodies—primarily limit new inflammatory activity to reduce relapses and new lesions. Many remain excellent options. However, they generally do not repair prior damage, and some people still accrue disability despite good relapse control.

The breakthroughs above aim to go further by attacking inflammation within the central nervous system, promoting remyelination, or—in the case of AHSCT—resetting the immune system at its roots. Practical upgrades matter, too: fewer or faster infusions, at‑home dosing options, and more precise monitoring can lower the burden of care and improve adherence.

What to ask your neurologist

Is my current disease course controlled? Review relapses, MRI activity, disability scores, and biomarkers (such as NfL) to establish whether a switch makes sense.
Which high‑efficacy options fit my profile? Discuss BTK inhibitors, anti‑CD20 therapies like ublituximab, or AHSCT candidacy based on age, comorbidities, and prior treatments.
Could I qualify for a clinical trial? Trials often provide access to cutting‑edge therapies and intensive monitoring. Search together on ClinicalTrials.gov.
What monitoring is needed? Ask about infusion reactions, infection risk, vaccine timing, lab tests, MRI frequency, and pregnancy planning.
What are the costs and logistics? Compare out‑of‑pocket costs, infusion center availability, time off work, and travel requirements.

Practical tips to navigate new treatments

Document your baseline: Keep a symptom diary, walking distance, fatigue levels, and any cognitive changes to gauge progress after a switch.
Plan vaccinations: Live vaccines may be restricted on certain therapies. Coordinate timing with your care team.
Build your support team: Include neurology, rehabilitation, mental health, and peer support. Organizations like NMSS and MSIF offer programs and communities.
Schedule reassessments: Revisit goals and MRI/biomarker data every 6–12 months to confirm the plan is working.

Key takeaways

New Multiple Sclerosis treatments are pushing beyond relapse control toward neuroprotection and remyelination.
BTK inhibitors, ublituximab, AHSCT, remyelination strategies, and EBV‑targeted approaches represent five of the most promising fronts.
Eligibility, benefits, and risks vary—partner closely with an MS specialist and consider clinical trial opportunities.

Trusted resources

Important: This article is for educational purposes only and isn’t a substitute for personalized medical advice. Always consult your neurologist about starting, stopping, or changing any MS therapy.